ADC drug giant cooperates with MSD in the first-line treatment of stage III bladder cancer

On December 2, Seattle genetics / Astaire announced a cooperation agreement with MSD to jointly carry out the clinical trial of enfortumab vedotin and keytruda in the first-line treatment of locally advanced or metastatic urothelial carcinoma Under the agreement, the three companies will fund the launch of a global registered phase III study, which will be led by Seattle genetics and is currently communicating with regulatory agencies on the pilot design, which is expected to start in the first half of 2020 Enfortumab vedotin has submitted a listing application to FDA for the treatment of locally advanced or metastatic urothelial carcinoma with PD-1 / L1 inhibitor and neoadjuvant / adjuvant chemotherapy containing platinum Currently, it is under FDA review The date of PDUFA is March 15 next year Enfortumab vedotin uses the proprietary connection technology of Seattle genetics to connect the microtubule destructor MMAE with anti-nectin-4 monoclonal antibody Enfortumab vedotin can target the cell adhesion molecule nectin-4 which is expressed on many solid tumors.